- Home
- PRKS vs RARE Comparison
PRKS vs RARE Comparison
Compare PRKS & RARE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | PRKS | RARE |
|---|---|---|
| Founded | 1959 | 2010 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Electromedical & Electrotherapeutic Apparatus | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.0B | 2.3B |
| IPO Year | 2012 | 2013 |
Fundamental Metrics
Financial Performance| Metric | PRKS | RARE |
|---|---|---|
| Price | $34.46 | $22.29 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 11 | 19 |
| Target Price | $49.27 | ★ $66.32 |
| AVG Volume (30 Days) | 1.3M | ★ 2.0M |
| Earning Date | 05-28-2026 | 05-04-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | 4.41 | ★ 7.31 |
| EPS | ★ 2.76 | N/A |
| Revenue | ★ $1,263,324,000.00 | $673,000,000.00 |
| Revenue This Year | $3.88 | $17.23 |
| Revenue Next Year | $3.07 | $36.13 |
| P/E Ratio | $12.29 | ★ N/A |
| Revenue Growth | N/A | ★ 20.13 |
| 52 Week Low | $29.62 | $18.41 |
| 52 Week High | $56.95 | $41.37 |
Technical Indicators
Market Signals| Indicator | PRKS | RARE |
|---|---|---|
| Relative Strength Index (RSI) | 45.20 | 42.28 |
| Support Level | $34.31 | $22.00 |
| Resistance Level | $37.44 | $23.79 |
| Average True Range (ATR) | 1.77 | 1.26 |
| MACD | -0.05 | 0.20 |
| Stochastic Oscillator | 42.58 | 54.69 |
Price Performance
Historical ComparisonAbout PRKS United Parks & Resorts Inc.
United Parks & Resorts Inc is an American theme park and entertainment company. Its core business is the operation of theme parks and entertainment facilities involving sea animals across the country under prominent brands such as SeaWorld, Busch Gardens, Aquatica, Discovery Cove, and Sesame Place. The company generates the majority of its revenue from selling admission tickets for its theme parks.
About RARE Ultragenyx Pharmaceutical Inc.
Ultragenyx Pharmaceutical Inc is a USA-based biopharmaceutical company. It identifies, acquires, develops, and commercializes novel products for the treatment of serious rare and ultra-rare diseases, with a focus on serious, debilitating genetic diseases. The company's medicine portfolio includes Crysvita, Dojolvi and Mepsevii. Crysvita is indicated for the treatment of X-linked hypophosphatemia (XLH) in adult and pediatric patients 1 year of age and older. Mepsevii is indicated in pediatric and adult patients for the treatment of Mucopolysaccharidosis VII.